Euclidean Capital
VC Fund
New York, United States
Euclidean Capital is an investment firm that invests in individual and family services management.
- Total investments:
- 65
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Euclidean Capital invests in
Stages Euclidean Capital invests in
Countries Euclidean Capital invests in
Round sizes
Round size
- Series A
- $24M–$85M
- Series B
- $21M–$185M
- Series C
- $46M–$120M
Investment Focus
Industry
- Biotechnology 20 (31%)
- Health Care 15 (23%)
- Medical 10 (15%)
- Therapeutics 10 (15%)
- Artificial Intelligence 6 (9%)
Stage
- Series B 16 (25%)
- Series A 13 (20%)
- Series C 11 (17%)
- Funding Round 5 (8%)
- Series E 4 (6%)
Country
- United States 33 (51%)
- India 2 (3%)
- Sweden 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nura Bio
|
Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M / Series B / Jun 22, 2026 | |
Ripple Foods
|
Ripple Foods specializes in making non-dairy milk with just as much protein as milk and half the sugar. Ripple has 8x the protein of almond milk and half the sugar of dairy milk. It’s high in bioavailable calcium (50% more than milk), potassium and provides a good source of omega-3s. It’s lower in calories than milk and best of all, it has thecreamy, delicious texture our dairy-free friends are missing. No more thin, chalky almond/ soy/ cashew milk.It was founded in 2014 and headquartered in Emeryville, California. | $17M / Dec 02, 2025 | |
Leal Therapeutics
|
Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 27, 2025 | |
SetPoint Medical
|
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $115M / Series D / Aug 11, 2025 | |
april
|
April has developed a tax platform that simplifies the filing process for U.S. taxpayers and enables better financial planning. | $38M / Series B / Jul 23, 2025 | |
Savvy Wealth
|
Savvy Wealth is a technology-enabled wealth management firm that provides a digital-first platform for financial advisors centered around optimizing human financial advice. With this platform, financial advisors utilize its purpose-built, integrated technology platform to help build organic growth with enhanced software and sales and marketingautomation. | $72M / Series B / Jul 02, 2025 | |
Actio Biosciences
|
Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients. | $66M / Series B / Jun 18, 2025 | |
Neurona Therapeutics
|
Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Series F / Apr 03, 2025 | |
Zeitview
|
Zeitview is an aerial data analytics platform that provides aerial drone services for energy and infrastructure sectors. Utilizing artificial intelligence and machine learning, the company analyzes visual data to provide actionable insights, enhancing asset performance and longevity. Zeitview serves industries such as solar, wind, propertymanagement, telecommunications, and utilities. Their platform delivers fast, accurate inspections, aiming to lower costs and improve operational efficiency. | $60M / Mar 05, 2025 | |
Neo Group
|
Neo Group is a Mumbai-based wealth and asset management platform. The company provides specialised, unbiased advisory and yield-oriented investment solutions to high-net-worth individuals (HNIs), ultra-high-net-worth individuals (UHNIs), family offices, institutions, and corporates. Its two core verticals are Wealth Management, offeringintergenerational and bespoke solutions for sophisticated global clients, and Asset Management, operating as India's preferred private markets manager providing sustainable solutions across private credit, core credit, equities, and real assets. | $20M / Venture - Series Unknown / Feb 01, 2025 | |
| See all 65 investments → | |||
Co-Investors
The Column Group
19 deals together
Alexandria Venture Investments
8 deals together
OUP (Osage University Partners)
6 deals together
Team8
6 deals together
Nextech Invest
5 deals together
OrbiMed
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Euclidean Capital invest in?
Euclidean Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Euclidean Capital's check size?
Euclidean Capital typically joins rounds of $24M–$85M at Series A, $21M–$185M at Series B and $46M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Euclidean Capital participates in.
When did Euclidean Capital last invest?
The most recent investment recorded for Euclidean Capital closed in Jun 2026. Shizune tracks 65 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
